Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 22 Mar 2002 |
| Novo Nordisk, development of AGM 12 March 2002 | 12 Mar 2002 |
| Novo Nordisk, annual review 2001 | 4 Mar 2002 |
| Novo Nordisk, trading in Novo Nordisk securities by the members of the Board of Directors and the Executive Committee | 28 Feb 2002 |
| Novo Nordisk, notice convening AGM 12 March 2002 | 26 Feb 2002 |